BHCM
CLPT icon

Brevan Howard Capital Management’s ClearPoint Neuro CLPT Stock Holding History

Brevan Howard Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,910
Closed -$142K – 1861
2025
Q1 		$142K Buy
+11,910
New +$185K ﹤0.01% 1023
2024
Q3 		– Sell
-13,218
Closed -$71.2K – 1175
2024
Q2 		$71.2K Buy
+13,218
New +$76.5K ﹤0.01% 991

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Brevan Howard Capital Management's CLPT Position: Q2 2025 in Review

Brevan Howard Capital Management sold out of ClearPoint Neuro (CLPT) in Q2 2025, closing a stake of 11,910 shares — an estimated $142K sold.

Brevan Howard Capital Management first reported a position in CLPT in Q2 2024 and held it in 2 quarters. The position peaked at $142K in Q1 2025. 96 funds tracked by Wall St. Rank hold CLPT as of Q2 2025.

  • Brevan Howard Capital Management reported no remaining ClearPoint Neuro position as of Q2 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 11,910 ClearPoint Neuro shares in Q2 2025, an estimated $142K.
  • Brevan Howard Capital Management first reported a position in ClearPoint Neuro in Q2 2024 and held it in 2 quarters.
  • Brevan Howard Capital Management's ClearPoint Neuro position peaked at $142K in Q1 2025.
  • 96 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2025.

Based on Brevan Howard Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.